Artiva Biotherapeutics (NASDAQ:ARTV) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright began coverage on shares of Artiva Biotherapeutics (NASDAQ:ARTV - Free Report) in a research note issued to investors on Monday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $20.00 price target on the stock.

Separately, Needham & Company LLC restated a "buy" rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $21.00.

Artiva Biotherapeutics Trading Down 0.6 %

Shares of ARTV stock traded down $0.06 during mid-day trading on Monday, reaching $10.58. 36,709 shares of the company were exchanged, compared to its average volume of 117,709. The company has a 50 day moving average price of $11.41. Artiva Biotherapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24). On average, research analysts predict that Artiva Biotherapeutics will post -4.68 EPS for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new position in Artiva Biotherapeutics in the 3rd quarter valued at about $42,000. MetLife Investment Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $135,000. JPMorgan Chase & Co. bought a new position in shares of Artiva Biotherapeutics in the third quarter valued at approximately $166,000. Barclays PLC acquired a new position in shares of Artiva Biotherapeutics during the third quarter valued at approximately $304,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in Artiva Biotherapeutics during the third quarter worth approximately $623,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.